Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Renal Cell Carcinoma: Future Directions in Care

April 22nd 2022

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

April 22nd 2022

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC

April 20th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Triplet Regimens in Development for Patients With RCC

April 20th 2022

Mehmet A. Bilen, MD, explains how triplet regiments might impact treatment selection for first line and beyond.

The Evaluation of Novel Agents and Combination Regimens in the First-Line Setting in RCC

April 20th 2022

The panel elaborates on novel agents and combination treatments that are currently being evaluated for the first-line setting in advanced RCC.

Dr. Choueiri on Next Steps for Pembrolizumab in RCC

April 19th 2022

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Patient Profile Presentation: A 48-Year-Old Man Presenting with a Right Renal Mass

April 19th 2022

Shawnta Anakwah, MD, presents the patient profile of a 48-year-old man with advanced renal cell carcinoma presenting with a right renal mass.

Duration of Treatment with IO-TKI Regimens and Treatment Options at Progression

April 19th 2022

Drs Anakwah and Basu share their thoughts on the duration of treatment with I/O–TKI regimens and what treatment options are available for patients at progression of renal cell carcinoma.

Adverse Events with IO-TKI Combination Regimens for Advanced RCC and Their Management

April 19th 2022

Experts review adverse events commonly observed with IO/TKI combination regimens in patients with RCC and how these are managed in clinical practice.

Selecting RCC Patients with Lenvatinib + Pembrolizumab Therapy and Appropriate Dosing Strategies

April 19th 2022

Oncologists discuss which patients with advanced RCC might be most suitable for treatment with lenvatinib + pembrolizumab and the appropriate dosing strategies for this regimen.

Dr. Ornstein on the Efficacy of Neoadjuvant Avelumab and Axitinib in RCC

April 18th 2022

Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.

Bempegaldesleukin/Nivolumab Combo Misses Mark in RCC and Urothelial Cancer

April 15th 2022

Nektar Therapeutics and Bristol Myers Squibb have announced the decision to end the global clinical development program for the combination of bempegaldesleukin and nivolumab based on findings from preplanned analyses of 2 late-stage clinical trials.

Patient Profile 4: Non–Clear Cell RCC Treated With Cabozantinib-Nivolumab

April 15th 2022

Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.

Clear Cell RCC: Testing Recommendations and Familial Risk

April 15th 2022

A brief discussion on the genetic risk tied to clear cell renal cell carcinoma and how that may inform familial risk and testing.

Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC

April 13th 2022

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Quality of Life Data From Clinical Trials in RCC

April 13th 2022

Dr Ornstein weighs in on interpreting quality of life data from important RCC trials to help with treatment decision-making.

Is There a Role for Biomarkers in Advanced RCC?

April 13th 2022

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with RCC.

Adjuvant and Neoadjuvant Therapies Under Evaluation for Renal Cell Carcinoma

April 8th 2022

Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab

April 8th 2022

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Treatment Strategies for Patients With RCC and Brain or Bone Metastases

April 6th 2022

Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.